Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Assets (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Assets for 16 consecutive years, with $1.6 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Assets rose 58.25% year-over-year to $1.6 billion, compared with a TTM value of $1.6 billion through Dec 2025, up 58.25%, and an annual FY2025 reading of $1.4 billion, up 21.54% over the prior year.
  • Assets was $1.6 billion for Q4 2025 at Arrowhead Pharmaceuticals, up from $1.4 billion in the prior quarter.
  • Across five years, Assets topped out at $1.6 billion in Q4 2025 and bottomed at $626.3 million in Q4 2023.
  • Average Assets over 5 years is $944.7 million, with a median of $839.8 million recorded in 2023.
  • The sharpest move saw Assets decreased 29.75% in 2023, then surged 64.74% in 2025.
  • Year by year, Assets stood at $638.5 million in 2021, then soared by 39.61% to $891.5 million in 2022, then fell by 29.75% to $626.3 million in 2023, then surged by 61.86% to $1.0 billion in 2024, then surged by 58.25% to $1.6 billion in 2025.
  • Business Quant data shows Assets for ARWR at $1.6 billion in Q4 2025, $1.4 billion in Q3 2025, and $1.4 billion in Q2 2025.